How we innovate
State-of-the-art processes from bench to bedside
Merck Serono is firmly founded upon innovation in pharmaceuticals. Here are some examples of how we bring this commitment
to life:
A biotech leader
One of our main areas of emphasis is biotechnology products such as antibodies and interferons. Five innovative biotech products
generate 60% of our total revenues.
Strong R&D commitment
Merck Serono has its own integrated research and development facilities as well as a network of alliances with other biotech companies and academic groups. Each year we invest 22% of total revenues to discover and develop new therapies.New approaches in cancer therapy
We are working on the development of therapies that specifically target cancer cells without damaging healthy cells. Merck Serono’s focus on the development of targeted cancer therapies is on three therapeutic platforms: targeting the tumor cell, the tumor environment and the immune system.Pioneering technology for patients
Merck Serono also works hard to make our medicines easier for patients to take. At the Medical Design Excellence Awards (MDEA) ceremony, Merck Serono’s easypod®, our first electronic growth hormone injection device, received a gold medal for its innovative design and ease of use. Easypod has been approved in Europe and North America and has already met with a positive response from patients and healthcare professionals in over 39 countries where it has been launched.Business Development at Merck Serono plays a key role in delivering new products to supplement the internal R&D pipeline.
Area of interest
Product opportunities in therapeutic areas aligned with the existing business units are of interest;
Neurology, Autoimmune and Inflammation, Reproductive Health, Growth Hormone, Cardiology, Diabetes & Oncology
Key interest drivers include products or near to market products used in a specialist care setting and with sales (or expected sales) in the UK and/or Europe (or subsets of European countries).
Exceptions to this will be considered on a case by case basis e.g. products or near to market products in other disease areas.
Opportunity Analysis Process
Merck Serono has a dedicated Business Development team covering the UK and Europe. Please direct queries to the contact information supplied.
After an initial discussion, a detailed review of the product offering will be undertaken. Information required includes sales data (including competition where appropriate), forecasts, patent position, a list of countries which are offered and outline deal type.
Contacts
Phone: 020 8818 7200
Area of interest
Product opportunities in therapeutic areas aligned with the existing business units are of interest;
Neurology, Autoimmune and Inflammation, Reproductive Health, Growth Hormone, Cardiology, Diabetes & Oncology
Key interest drivers include products or near to market products used in a specialist care setting and with sales (or expected sales) in the UK and/or Europe (or subsets of European countries).
Exceptions to this will be considered on a case by case basis e.g. products or near to market products in other disease areas.
Opportunity Analysis Process
Merck Serono has a dedicated Business Development team covering the UK and Europe. Please direct queries to the contact information supplied.
After an initial discussion, a detailed review of the product offering will be undertaken. Information required includes sales data (including competition where appropriate), forecasts, patent position, a list of countries which are offered and outline deal type.
Contacts
Phone: 020 8818 7200
